April 25 (Reuters) - Aralez Pharmaceuticals Inc ARZ.TO
* Aralez pharmaceuticals says Health Canada approved BLEXTEN
for treatment of symptoms of seasonal allergic rhinitis, chronic
spontaneous urticaria
* BLEXTEN will be distributed in Canada by Tribute
Pharmaceuticals Canada Inc., a subsidiary of company
Source text for Eikon: ID:nPn7qQrnfa
Further company coverage: ARZ.TO
(Bengaluru Newsroom: +1 646 223 8780)